SPY380.36-1.97 -0.52%
DIA309.45-4.53 -1.44%
IXIC13,192.35+72.96 0.56%

BRIEF-Spero Therapeutics Provides Update On SPR720 Phase 2A Clinical Trial

· 02/05/2021 08:04
BRIEF-Spero Therapeutics Provides Update On SPR720 Phase 2A Clinical Trial

- Spero Therapeutics Inc SPRO.O:

  • SPERO THERAPEUTICS PROVIDES UPDATE ON SPR720 PHASE 2A CLINICAL TRIAL

  • SPERO THERAPEUTICS INC - FDA INFORMED SPERO THAT A CLINICAL HOLD HAS BEEN PLACED ON ITS PHASE 2A CLINICAL TRIAL OF SPR720

  • SPERO THERAPEUTICS INC - RECEIVED VERBAL NOTIFICATION OF CLINICAL HOLD FOR SPR720 PHASE 2A TRIAL BUT HAS NOT YET RECEIVED WRITTEN NOTICE FROM FDA

  • SPERO THERAPEUTICS - CLINICAL HOLD FOLLOWS NOTIFICATION BY CO OF ITS DECISION TO PAUSE DOSING IN PHASE 2A TRIAL OF SPR720 AS A PRECAUTIONARY MEASURE

  • SPERO THERAPEUTICS - DECISION TO IMPLEMENT PAUSE WAS MADE BASED ON A RECOMMENDATION FROM SPERO'S SAFETY REVIEW BOARD

  • SPERO THERAPEUTICS INC - CO IS IN DISCUSSION WITH FDA TO EVALUATE FINDINGS AND DETERMINE FURTHER DEVELOPMENT PATHWAY FOR SPR720 CLINICAL PROGRAM

  • SPERO THERAPEUTICS - NO SERIOUS ADVERSE EVENTS HAVE BEEN OBSERVED IN ANY HUMAN STUDY PARTICIPANTS IN SPR720 PHASE 2A CLINICAL TRIAL

  • SPERO THERAPEUTICS - IN A TOXICOLOGY STUDY OF SPR720 IN ADULT NON-HUMAN PRIMATES, MORTALITIES WITH INCONCLUSIVE CAUSALITY TO TREATMENT WERE OBSERVED

Source text for Eikon: ID:nGNXbryFJf

Further company coverage: SPRO.O


((Reuters.Briefs@thomsonreuters.com;))